FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2983804219> ?p ?o ?g. }

• W2983804219 endingPage "5249" @default.
• W2983804219 startingPage "5249" @default.
• W2983804219 abstract "Background and objective. Idelalisib is an oral inhibitor of the p110δ isoform of PI3K (phosphoinositide 3-kinase) approved in Europe and USA as monotherapy in relapsed/refractory follicular lymphoma (FL) after 2 previous lines of therapy based on a phase 2 study (Gopal et al, N Eng J Med 2014). However, there are scarce data on the use of idelalisib in clinical practice (Eyre et al, Br J Haematol 2017). The objective of this study was to analyze the efficacy and toxicity of idelalisib in relapsed/refractory FL patients in clinical practice in Spanish hospitals of GELTAMO group (GELT-IDE-2018-02 Study). Patients and Methods. Retrospective study of relapsed/refractory FL patients treated with idelalisib as salvage therapy in clinical practice. Demographic and clinical and biological variables were analyzed at FL diagnosis and at the time of idelalisib therapy, as well as its efficacy and toxicity. Results. A total of 43 patients from 20 hospitals were included. At time of idelalisib therapy, median age was 63 years (range 44-83), number of previous lines of therapy was 3 (2-7), 42% (n=18) were refractory to last previous treatment and 42% (n=18) had received an autologous stem cell transplantation (SCT); 56% (n=24) had progressed in the first 24 months after FL diagnosis (POD24). Median duration of treatment with idelalisib at time of analysis was 8.1 months (1.1-37.4) and 28/43 patients (65%) discontinued therapy, 13 due to progression, 12 due to adverse events (AE) and 3 due to physician's decision. Overall response rate (ORR) was 73% (32% CR) and median PFS 14.6 months (95% CI 0-32.2), with a trend to be higher in non-POD24 group (median PFS of 9.4 months [95% CI 1.7-16.9] in POD24 vs. 27 months [95% CI NA] in non-PO24 patients, p=0.082); median duration of response to idelalisib was 25.1 months (95% CI 13.1-37.6). Median overall survival (OS) was not reached at the time of analysis, with a 2-year OS of 74% (95% CI 58%-90%) (Figure). In 4 patients, an allogeneic SCT was performed after idelalisib. A total of 86% (n=37) of patients showed any AE, being in 56% (n=24) of grade ≥3 AE. Toxicities of grade ≥3 more frequent were: neutropenia (23% of patients), diarrhea (23%), infections (23%: pneumonia in 4 patients, CMV infection in 2, febrile neutropenia in 1 and other infections in 3 [1 of them died due to Aspergillus infection]), and increased transaminases (9%). Conclusions. In this series of patients with relapsed/refractory FL, several previous lines of therapies and factors associated with poor prognosis, the treatment with idelalisib was associated with efficacy and toxicity similar to published studies. These results support the use of idelalisib as an option for FL patients with multiple or poor risk relapses. Financial support: Gilead Figure. Progression-free survival (PFS) and overall survival (OS) for patients with follicular lymphoma treated with idelalisib. Figure Disclosures Sancho: SERVIER: Honoraria; SANOFI: Honoraria; Novartis: Consultancy, Honoraria; CELGENE: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; JANSSEN: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; ROCHE: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; GILEAD: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; CELLTRION: Consultancy; Kern-Pharma: Honoraria; Sandoz: Consultancy. Lopez Jimenez:GILEAD SCIENCES: Honoraria, Other: Education funding. Ramirez Payer:GILEAD SCIENCES: Research Funding. Cordoba:Janssen: Consultancy, Honoraria, Speakers Bureau; Servier: Consultancy, Honoraria, Speakers Bureau; Kyowa-Kirin: Consultancy, Honoraria, Speakers Bureau; Gilead: Consultancy, Research Funding, Speakers Bureau; Roche: Honoraria, Speakers Bureau; FUNDACION JIMENEZ DIAZ UNIVERSITY HOSPITAL: Employment; Celgene: Consultancy, Honoraria, Speakers Bureau; Pfizer: Consultancy. Martín:Kiowa Kirin: Consultancy; Gilead: Consultancy, Honoraria; Celgene: Consultancy, Honoraria, Other: Travel Expenses, Research Funding; iQone: Consultancy; Teva: Research Funding; Janssen: Honoraria, Other: Travel Expenses, Research Funding; Roche: Consultancy, Honoraria, Other: Travel Expenses; Servier: Honoraria, Other: Travel Expenses. Armando:Roche: Consultancy, Research Funding; Janssen: Research Funding; Gilead: Consultancy, Research Funding; Celgene: Consultancy, Research Funding." @default.
• W2983804219 created "2019-11-22" @default.
• W2983804219 creator A5004171353 @default.
• W2983804219 creator A5006538688 @default.
• W2983804219 creator A5015394751 @default.
• W2983804219 creator A5021355219 @default.
• W2983804219 creator A5021543091 @default.
• W2983804219 creator A5023762547 @default.
• W2983804219 creator A5026996844 @default.
• W2983804219 creator A5029088164 @default.
• W2983804219 creator A5029384169 @default.
• W2983804219 creator A5036922520 @default.
• W2983804219 creator A5041947496 @default.
• W2983804219 creator A5042060010 @default.
• W2983804219 creator A5046137360 @default.
• W2983804219 creator A5050980478 @default.
• W2983804219 creator A5052821264 @default.
• W2983804219 creator A5054404140 @default.
• W2983804219 creator A5056416386 @default.
• W2983804219 creator A5058264336 @default.
• W2983804219 creator A5062060671 @default.
• W2983804219 creator A5071261900 @default.
• W2983804219 creator A5077730260 @default.
• W2983804219 creator A5083191976 @default.
• W2983804219 creator A5091853226 @default.
• W2983804219 date "2019-11-13" @default.
• W2983804219 modified "2023-10-16" @default.
• W2983804219 title "Idelalisib for Relapsed/Refractory Follicular Lymphoma: Retrospective Study from Spanish Lymphoma Group Geltamo (GELT-IDE-2018-02)" @default.
• W2983804219 doi "https://doi.org/10.1182/blood-2019-125921" @default.
• W2983804219 hasPublicationYear "2019" @default.
• W2983804219 type Work @default.
• W2983804219 sameAs 2983804219 @default.
• W2983804219 citedByCount "0" @default.
• W2983804219 crossrefType "journal-article" @default.
• W2983804219 hasAuthorship W2983804219A5004171353 @default.
• W2983804219 hasAuthorship W2983804219A5006538688 @default.
• W2983804219 hasAuthorship W2983804219A5015394751 @default.
• W2983804219 hasAuthorship W2983804219A5021355219 @default.
• W2983804219 hasAuthorship W2983804219A5021543091 @default.
• W2983804219 hasAuthorship W2983804219A5023762547 @default.
• W2983804219 hasAuthorship W2983804219A5026996844 @default.
• W2983804219 hasAuthorship W2983804219A5029088164 @default.
• W2983804219 hasAuthorship W2983804219A5029384169 @default.
• W2983804219 hasAuthorship W2983804219A5036922520 @default.
• W2983804219 hasAuthorship W2983804219A5041947496 @default.
• W2983804219 hasAuthorship W2983804219A5042060010 @default.
• W2983804219 hasAuthorship W2983804219A5046137360 @default.
• W2983804219 hasAuthorship W2983804219A5050980478 @default.
• W2983804219 hasAuthorship W2983804219A5052821264 @default.
• W2983804219 hasAuthorship W2983804219A5054404140 @default.
• W2983804219 hasAuthorship W2983804219A5056416386 @default.
• W2983804219 hasAuthorship W2983804219A5058264336 @default.
• W2983804219 hasAuthorship W2983804219A5062060671 @default.
• W2983804219 hasAuthorship W2983804219A5071261900 @default.
• W2983804219 hasAuthorship W2983804219A5077730260 @default.
• W2983804219 hasAuthorship W2983804219A5083191976 @default.
• W2983804219 hasAuthorship W2983804219A5091853226 @default.
• W2983804219 hasConcept C121332964 @default.
• W2983804219 hasConcept C126322002 @default.
• W2983804219 hasConcept C142424586 @default.
• W2983804219 hasConcept C143998085 @default.
• W2983804219 hasConcept C197934379 @default.
• W2983804219 hasConcept C2776694085 @default.
• W2983804219 hasConcept C2777058707 @default.
• W2983804219 hasConcept C2777938653 @default.
• W2983804219 hasConcept C2778461978 @default.
• W2983804219 hasConcept C2779260929 @default.
• W2983804219 hasConcept C2779338263 @default.
• W2983804219 hasConcept C2779878957 @default.
• W2983804219 hasConcept C2780775027 @default.
• W2983804219 hasConcept C71924100 @default.
• W2983804219 hasConcept C87355193 @default.
• W2983804219 hasConcept C90924648 @default.
• W2983804219 hasConceptScore W2983804219C121332964 @default.
• W2983804219 hasConceptScore W2983804219C126322002 @default.
• W2983804219 hasConceptScore W2983804219C142424586 @default.
• W2983804219 hasConceptScore W2983804219C143998085 @default.
• W2983804219 hasConceptScore W2983804219C197934379 @default.
• W2983804219 hasConceptScore W2983804219C2776694085 @default.
• W2983804219 hasConceptScore W2983804219C2777058707 @default.
• W2983804219 hasConceptScore W2983804219C2777938653 @default.
• W2983804219 hasConceptScore W2983804219C2778461978 @default.
• W2983804219 hasConceptScore W2983804219C2779260929 @default.
• W2983804219 hasConceptScore W2983804219C2779338263 @default.
• W2983804219 hasConceptScore W2983804219C2779878957 @default.
• W2983804219 hasConceptScore W2983804219C2780775027 @default.
• W2983804219 hasConceptScore W2983804219C71924100 @default.
• W2983804219 hasConceptScore W2983804219C87355193 @default.
• W2983804219 hasConceptScore W2983804219C90924648 @default.
• W2983804219 hasIssue "Supplement_1" @default.
• W2983804219 hasLocation W29838042191 @default.
• W2983804219 hasOpenAccess W2983804219 @default.
• W2983804219 hasPrimaryLocation W29838042191 @default.
• W2983804219 hasRelatedWork W1973891791 @default.
• W2983804219 hasRelatedWork W2040492280 @default.
• W2983804219 hasRelatedWork W2045177263 @default.
• W2983804219 hasRelatedWork W2105293222 @default.
• W2983804219 hasRelatedWork W2123990658 @default.

• next